These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23583814)

  • 1. Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs.
    Donauer S; Payne DC; Edwards KM; Szilagyi PG; Hornung RW; Weinberg GA; Chappell J; Hall CB; Parashar UD; Staat MA
    Vaccine; 2013 May; 31(24):2692-7. PubMed ID: 23583814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.
    Leshem E; Givon-Lavi N; Tate JE; Greenberg D; Parashar UD; Dagan R
    Clin Infect Dis; 2016 May; 62 Suppl 2():S155-60. PubMed ID: 27059350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013.
    Payne DC; Selvarangan R; Azimi PH; Boom JA; Englund JA; Staat MA; Halasa NB; Weinberg GA; Szilagyi PG; Chappell J; McNeal M; Klein EJ; Sahni LC; Johnston SH; Harrison CJ; Baker CJ; Bernstein DI; Moffatt ME; Tate JE; Mijatovic-Rustempasic S; Esona MD; Wikswo ME; Curns AT; Sulemana I; Bowen MD; Gentsch JR; Parashar UD
    Clin Infect Dis; 2015 Dec; 61(12):1792-9. PubMed ID: 26449565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
    Dennehy PH; Vesikari T; Matson DO; Itzler RF; Dallas MJ; Goveia MG; DiNubile MJ; Heaton PM; Ciarlet M
    Hum Vaccin; 2011 May; 7(5):563-8. PubMed ID: 21441783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011.
    Payne DC; Boom JA; Staat MA; Edwards KM; Szilagyi PG; Klein EJ; Selvarangan R; Azimi PH; Harrison C; Moffatt M; Johnston SH; Sahni LC; Baker CJ; Rench MA; Donauer S; McNeal M; Chappell J; Weinberg GA; Tasslimi A; Tate JE; Wikswo M; Curns AT; Sulemana I; Mijatovic-Rustempasic S; Esona MD; Bowen MD; Gentsch JR; Parashar UD
    Clin Infect Dis; 2013 Jul; 57(1):13-20. PubMed ID: 23487388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatrics; 2010 Feb; 125(2):e208-13. PubMed ID: 20100757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.
    Boom JA; Tate JE; Sahni LC; Rench MA; Hull JJ; Gentsch JR; Patel MM; Baker CJ; Parashar UD
    Pediatrics; 2010 Feb; 125(2):e199-207. PubMed ID: 20083525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).
    Itzler R; Koch G; Matson DO; Gothefors L; Van Damme P; Dinubile MJ; Heaton PM
    BMC Pediatr; 2010 Jun; 10():42. PubMed ID: 20540778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of pentavalent rotavirus vaccine against severe disease.
    Staat MA; Payne DC; Donauer S; Weinberg GA; Edwards KM; Szilagyi PG; Griffin MR; Hall CB; Curns AT; Gentsch JR; Salisbury S; Fairbrother G; Parashar UD;
    Pediatrics; 2011 Aug; 128(2):e267-75. PubMed ID: 21768317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine.
    Tate JE; Curns AT; Cortese MM; Weintraub ES; Hambidge S; Zangwill KM; Patel MM; Baggs JM; Parashar UD
    Pediatrics; 2009 Mar; 123(3):744-9. PubMed ID: 19254997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact.
    Pindyck T; Tate JE; Parashar UD
    Expert Rev Vaccines; 2018 Jul; 17(7):593-606. PubMed ID: 29909693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting.
    Doll MK; Buckeridge DL; Morrison KT; Gagneur A; Tapiero B; Charest H; Quach C
    Vaccine; 2015 Dec; 33(51):7307-7314. PubMed ID: 26546262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of vaccination with the pentavalent rotavirus vaccine in Nicaragua as determined using the screening method.
    Cardellino A; Khawaja S; Sánchez Cruz E; Mast TC
    Hum Vaccin Immunother; 2013 Jul; 9(7):1449-53. PubMed ID: 23571175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia.
    Field EJ; Vally H; Grimwood K; Lambert SB
    Pediatrics; 2010 Sep; 126(3):e506-12. PubMed ID: 20732946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of monovalent and pentavalent rotavirus vaccine.
    Cortese MM; Immergluck LC; Held M; Jain S; Chan T; Grizas AP; Khizer S; Barrett C; Quaye O; Mijatovic-Rustempasic S; Gautam R; Bowen MD; Moore J; Tate JE; Parashar UD; Vázquez M
    Pediatrics; 2013 Jul; 132(1):e25-33. PubMed ID: 23776114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-Level Impact of Ontario's Infant Rotavirus Immunization Program: Evidence of Direct and Indirect Effects.
    Wilson SE; Rosella LC; Wang J; Le Saux N; Crowcroft NS; Harris T; Bolotin S; Deeks SL
    PLoS One; 2016; 11(5):e0154340. PubMed ID: 27168335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua.
    Mast TC; Khawaja S; Espinoza F; Paniagua M; Del Carmen LP; Cardellino A; Sánchez E
    Pediatr Infect Dis J; 2011 Nov; 30(11):e209-15. PubMed ID: 21768920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries.
    El Khoury AC; Mast TC; Ciarlet M; Markson LE; Goveia MG
    Hum Vaccin; 2011 May; 7(5):506-10. PubMed ID: 21422820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice.
    Bégué RE; Perrin K
    Pediatrics; 2010 Jul; 126(1):e40-5. PubMed ID: 20587671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.